Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNB1 | Q14721 | 13/20 | 0.59 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.59 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28402845 | 0.88 | KCNB1 (0.60) | KCNB1KCNA5KCNH2KCNK2TDP1 | |
| SCHEMBL13077332 | 0.88 | KCNB1 (0.60) | KCNB1KCNA5KCNH2KCNK2TDP1 | |
| SCHEMBL28408420 | 0.86 | KCNB1 (0.60) | KCNB1KCNA5KCNH2KCNK2TDP1 | |
| SCHEMBL28406257 | 0.80 | KCNB1 (0.77) | KCNB1KCNA5KCNH2KCNK2 | |
| SCHEMBL29793640 | 0.80 | KCNB1 (0.72) | KCNB1KCNA5KCNH2KCNK2TSHR | |
| SCHEMBL28890737 | 0.80 | KCNB1 (0.72) | KCNB1KCNA5KCNH2KCNK2TSHR | |
| SCHEMBL29793697 | 0.80 | KCNB1 (0.77) | KCNB1KCNA5KCNH2KCNK2 | |
| SCHEMBL13815085 | 0.79 | MAPT (0.52) | MAPT | |
| SCHEMBL28408170 | 0.78 | KCNB1 (0.81) | KCNB1KCNA5KCNH2KCNK2 | |
| SCHEMBL28402836 | 0.77 | KCNB1 (0.63) | KCNB1KCNA5KCNH2KCNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929263-B | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-22 | — | — | CN | disclosed |